The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.

International journal of oncology

Volumn 26, Issue 6, 2005, Pages 1507-1515

  Menendez, Javier A ^a   Oza, Bharvi P ^a   Colomer, Ramon ^a   Lupu, Ruth ^a  

^a EVANSTON NORTHWESTERN HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; FATTY ACID SYNTHASE; NORETYNODREL; ORAL CONTRACEPTIVE AGENT; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CONTRACEPTIVES, ORAL; ESTROGENS; FATTY ACID SYNTHETASE COMPLEX; FEMALE; HUMANS; NORETHYNODREL; PROGESTERONE CONGENERS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 22344436414     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.26.6.1507     Document Type: Article

References (0)